EMERGO EUROPE

24 March 2009

Mr. Jeff Wang
LumiQuick Diagnostics, Inc.
2946 Scott Blvd.
Santa Clara, CA 95054

Dear Mr.Jeff Wang:

I am writing to inform you that today, we have notified by registered mail the Competent Authority in the following countries:

Austria	Bulgaria	Cyprus	Czech Republic	Denmark	Estonia
Finland	France	Germany	Greece	Hungary	Iceland
Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg
Malta	The Netherlands		Norway	Poland	Portugal
Romania	Slovakia	Slovenia	Spain	Sweden	Switzerland
United Kingdom					

With this notification, LumiQuick Diagnostics, Inc. has met the requirements of the In-vitro Diagnostics Directive, 98/79/EC for the following devices:

- Adeno/Rota Virus
- Cardiac Marker
- Dengue IgG/IgM Combo (registered only in Italy and The Netherlands)
- Drugs of Abuse
- Fecal Occult Blood (registered only in Italy and The Netherlands)
- H. Pylori Ab/Ag
- HCG
- Legionella (registered only in Italy and The Netherlands)
- LH (registered only in Italy and The Netherlands)
- Strep A (registered only in Italy and The Netherlands)

As of today and without any further notice from the respective Competent Authorities, LumiQuick Diagnostics, Inc. can consider the respective devices and Authorized Representative as officially registered.

If you have any questions, please do not hesitate to contact me.

Yours sincerely,

Rene van de Zande
President & CEO
Emergo Europe

REPUBLICA MOLDOVA, mun. CHIŞINĂU S.R.L. "SANMEDICO" IDNO 1003600008154 SOCIETATEA CU RĂSPUNDERE LIMITATĂ

EmergoEurope.com

Digitally signed by Monastîrschii Viorica
Date: 2021.03.05 13:18:57 EET
Reason: MoldSign Signature
Location: Moldova

bsi.

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

LumiQuick Diagnostics, Inc.
2946 Scott Blvd
Santa Clara
California
95054
USA

Holds Certificate No: **FM 574919**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

The design, development, manufacture and distribution of in vitro diagnostics test kits and reagents used in the diagnosis and management of disease status, including Infectious Diseases tests, Drugs of Abuse tests, Cardiac Monitor tests, Cancer Marker tests, Fertility Hormone tests, ELISA tests & Urine Chemistry tests.

For and on behalf of BSI:

Gary E Slack, Senior Vice President - Medical Devices

Original Registration Date: 2011-10-20
Latest Revision Date: 2020-08-31

Effective Date: 2020-10-20
Expiry Date: 2023-10-19

...making excellence a habit.™